Source avec lien : American Journal of Infection Control, (Prépublication), . 10.1016/j.ajic.2021.02.012
Avec une saison grippale unique qui se déroule en pleine pandémie, il est intéressant d’évaluer le rôle du vaccin antigrippal dans la sensibilité et la gravité de la COVID-19. Dans cette étude de cohorte rétrospective, on a identifié les patients qui ont subi un test de laboratoire pour la COVID-19. Cette étude de cohorte rétrospective a permis d’identifier les patients ayant subi un test de laboratoire pour le COVID-19. Les points d’aboutissement secondaires chez les patients ayant obtenu un résultat positif au test COVID-19 comprenaient la mortalité, la nécessité d’une hospitalisation, la durée du séjour, la nécessité de soins intensifs et la ventilation mécanique.
Background With a unique influenza season occurring in the midst of a pandemic, there is interest in assessing the role of the influenza vaccine in COVID-19 susceptibility and severity. Methods In this retrospective cohort study, patients receiving a laboratory test for COVID-19 were identified. The primary outcome was comparison of positive COVID-19 testing in those who received the influenza vaccine versus those who did not. Secondary end points in patients testing positive for COVID-19 included mortality, need for hospitalization, length of stay, need for intensive care, and mechanical ventilation. Results A total of 27,201 patients received laboratory testing for COVID-19. The odds of testing positive for COVID-19 was reduced in patients who received an influenza vaccine compared to those who did not (odds ratio 0.76, 95% CI 0.68 to 0.86; P < 0.001). Vaccinated patients testing positive for COVID-19 were less likely to require hospitalization (odds ratio, 0.58, 95% CI 0.46 to 0.73; P < 0.001), or mechanical ventilation (odds ratio, 0.45, 95% CI 0.27 to 0.78; P = 0.004) and had a shorter hospital length of stay (risk ratio, 0.76, 95% CI 0.65 to 0.89; P <0.001). Conclusion Influenza vaccination is associated with decreased positive COVID-19 testing and improved clinical outcomes and should be promoted to reduce the burden of COVID-19.